P. Vrignaud

发表

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

D. Bergstrom, Weidong Zhang, C. Dib, 2015, Cancer research.

Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.

P. Vrignaud, F. Lévi, T. Granda, 2001, Cancer research.

From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase

P. Vrignaud, M. Bissery, J. Riou, 2001 .

Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography

P. Vrignaud, S. Koscielny, N. Lassau, 2008, Investigative radiology.

Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.

P. Vrignaud, L. Mauriac, J. Robert, 1985, Cancer treatment reports.

Production of the Bengamide Class of Marine Natural Products in Myxobacteria: Biosynthesis and Structure-Activity Relationships.

P. Vrignaud, J. Nicolas, L. Debussche, 2015, Angewandte Chemie.

Docetaxel chronopharmacology in mice.

P. Vrignaud, F. Lévi, E. Filipski, 1998, Cancer research.

Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice

P. Vrignaud, M. Bissery, G. Chabot, 1996, Anti-cancer drugs.

Assessment of the experimental model of transplanted C6 glioblastoma in wistar rats

P. Vrignaud, J. Robert, J. Coindre, 1989, Journal of Neuro-Oncology.

Efficacy of cabazitaxel in mouse models of pediatric brain tumors.

Emily J. Girard, J. Olson, P. Vrignaud, 2015, Neuro-oncology.

Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.

P. Vrignaud, S. Kuduk, J. Veith, 1996, Journal of medicinal chemistry.

antitumor combinations containing Vegt inhibitor agent and a 5-FU or its derivatives

P. Vrignaud, J. Cedarbaum, E. Furfine, 2004 .

Preclinical Antitumor Activity and Pharmacokinetics of Irinotecan (CPT‐11) in Tumor‐bearing Mice

P. Vrignaud, M. Bissery, G. Chabot, 1996, Annals of the New York Academy of Sciences.

RPR 130401, a Nonpeptidomimetic Farnesyltransferase Inhibitor with in Vivo Activity

P. Vrignaud, P. Mailliet, F. Lavelle, 1999, Annals of the New York Academy of Sciences.

Preclinical profile of cabazitaxel

P. Vrignaud, Sunil Gupta, H. Bouchard, 2014, Drug design, development and therapy.

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

P. Vrignaud, M. Bissery, J. Riou, 2013, Clinical Cancer Research.

Novel Taxanes: Cabazitaxel Case Study

P. Vrignaud, H. Bouchard, D. Sémiond, 2012 .

Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture.

P. Vrignaud, J. Robert, D. Londos-Gagliardi, 1986, Oncology.

Cellular pharmacology of 4'-iodo-4'-deoxydoxorubicin.

P. Vrignaud, J. Robert, B. Schott, 1990, British Journal of Cancer.

Fatty Acid Composition Transport and Metabolism in Doxorubicin-sensitive and-resistant Rat Glioblastoma Cells 1

P. Vrignaud, J. Robert, D. Montaudon, 2006 .

Evaluation of tissue perfusion (tumor, spleen, heart) in mice after administration of AVE8062, a tumor vascular-targeting agent

P. Vrignaud, M. Bissery, M. Guffroy, 2004 .

Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients.

P. Vrignaud, J. Robert, A. Iliadis, 1985, European journal of cancer & clinical oncology.

Preclinical evaluation of TXD258, a new taxoid

P. Vrignaud, J. Riou, H. Bouchard, 2000 .

Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.

P. Opolon, P. Vrignaud, B. Geoerger, 2010, European journal of cancer.

Tentative dose-monitoring of doxorubicin in lymphoma patients

P. Vrignaud, J. Robert, T. Nguyen-Ngoc, 1985, Medical oncology and tumor pharmacotherapy.

Alteration of ganglioside composition and metabolism in doxorubicin-resistant rat tumoral cells.

P. Vrignaud, M. Benchekroun, D. Montaudon, 1988, Biochimica et biophysica acta.

Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel

P. Vrignaud, S. Sidhu, M. Bissery, 2013, Cancer Chemotherapy and Pharmacology.

Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.

P. Vrignaud, M. Bissery, F. Lavelle, 1995, Seminars in oncology.

Synthesis and structure-activity relationships of new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of taxotere (docetaxel).

P. Vrignaud, J. Riou, I. Ojima, 1994, Journal of medicinal chemistry.

Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer

Philippe Dessen, Hany Soliman, Peggy Dartigues, 2012, Clinical Cancer Research.

Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.

P. Vrignaud, C. Nguyen, J. Riou, 1995, Anti-cancer drug design.

Setting up a wide panel of patient-derived tumor xenografts of non–small cell lung cancer by improving the preanalytical steps

P. Vrignaud, A. Merino-Trigo, E. Selva, 2014, Cancer medicine.

Fluorescence anisotropy of cell membranes of doxorubicin-sensitive and -resistant rodent tumoral cells.

P. Vrignaud, J. Robert, D. Montaudon, 1986, Cancer research.

Pharmacokinetics of doxorubicin in sarcoma patients

P. Vrignaud, J. Robert, N. B. Bui, 2004, European Journal of Clinical Pharmacology.

Early-phase pharmacokinetics of doxorubicin in non-hodgkin lymphoma patients

P. Vrignaud, J. Robert, B. Hoerni, 1983, Cancer Chemotherapy and Pharmacology.

Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice

P. Vrignaud, C. Nguyen, M. Bissery, 1993, Investigational New Drugs.

Fatty acid composition transport and metabolism in doxorubicin-sensitive and-resistant rat glioblastoma cells.

P. Vrignaud, J. Robert, D. Montaudon, 1986, Cancer research.

Preclinical evaluation of docetaxel (Taxotere).

P. Vrignaud, M. Bissery, J. Riou, 1995, Seminars in oncology.

Generation of a Conditionally Transformed Murine Embryonic Fibroblast Cell Line Using Doxycycline-Dependent IGF-1R Overexpression

M. Kubbutat, P. Vrignaud, M. Chiron, 2012, Journal of biomolecular screening.

Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated prefused rat liver

P. Vrignaud, J. Robert, R. Poupon, 2004, Cancer Chemotherapy and Pharmacology.

Hepatic metabolism of doxorubicin in mice and rats

P. Vrignaud, J. Robert, D. Londos-Gagliardi, 1985, European Journal of Drug Metabolism and Pharmacokinetics.

525 POSTER Preclinical evaluation of SAR566658 (huDS6-DM4) in mice bearing human tumor xenografts of breast, ovarian, lung, cervical and pancreatic cancer

P. Vrignaud, R. Lutz, V. Blanc, 2008 .

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma

P. Vrignaud, F. Lévi, T. Granda, 2002, British Journal of Cancer.

In vivo evaluation of the lrinotecan-oxaliplatin comblnation

P. Vrignaud, M. Bissery, 1997 .

A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model

Christina Mazcko, Amy K. LeBlanc, Jessica Lawrence, 2016, PloS one.

Mechanisms of Resistance to Cabazitaxel

P. Vrignaud, B. Sikic, J. C. Rose, 2014, Molecular Cancer Therapeutics.

Metabolism of doxorubicin and epirubicin in adult human hepatocytes in culture.

P. Vrignaud, J. Robert, F. Ballet, 1986, Pharmacological research communications.

In vivo synergy between trastuzumab (herceptin ® ) and larotaxel (RPR 109881A), a new taxoid.

P. Vrignaud, M. Chiron, M. Bissery, 2007 .

In vivo synergy between doxorubicin, cisplatin or vinorelbine and RPR 109881A, a new taxoid

P. Vrignaud, M. Bissery, P. Lejeune, 2005 .

Fatty Acid Composition and Metabolism of Tumor Cells Rendered Resistant to the Anticancer Drug Doxorubicin

P. Vrignaud, J. Robert, D. Montaudon, 1986 .

Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel or gemcitabine results in greater antitumor activity in tumor bearing mice.

P. Vrignaud, M. Chiron, M. Bissery, 2008 .

Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models

P. Vrignaud, W. Leopold, M. Chiron, 2007 .

Mechanisms of Resistance to Cabazitaxel

P. Vrignaud, B. Sikic, J. C. Rose, 2014, Molecular Cancer Therapeutics.

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

D. Bergstrom, Weidong Zhang, C. Dib, 2015, Cancer research.